Sanofi produces more Lemtrada data ahead of second FDA approval decision
This article was originally published in Scrip
Executive Summary
Sanofi subsidiary Genzyme has released interim results from the second year of an extension study for multiple sclerosis drug Lemtrada (alemtuzmab), which show that relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug in Phase III trials.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.